32 results about "Sialidase activity" patented technology

The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.

Provided herein are novel irreversible sialidase inhibitors. These compounds can be conjugated with a detectable tagging moiety such as azide-annexed biotin via CuAAC for isolation and identification of sialidases. The provided compounds and the corresponding detectable conjugates are useful for detecting sialidase-containing pathogens and imaging in situ sialidase activities under physiological conditions.

The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.

Isolated polypeptide having sialidase activity and having an amino acid sequence which has at least 90% amino acid sequence identity with amino acids 34 to 407 of SEQ ID NO: 3.

The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.

The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation. Sialidase activity is reduced and the proliferation of one or more bacteria is inhibited, as compared to a platelet product preparation not subjected to the sialidase inhibitor treatment.

The present invention provides mutants of PmST1 for the preparation of sialyl-Lewisx oligosaccharides, and other sialosides with decreased sialidase activity.

The invention provides a sialidase enzyme activity detection kit or device comprising: (i) an indicator molecule comprising a sialylated peptide and a capture site; (ii) a capture zone comprising capture molecules; and (iii) binding molecules capable of binding to the de-sialylated derivative of the indicator molecule. Also provided are methods of using the kits or devices, as well as specific indicator molecules and specific binding molecules.

The invention provides a method for evaluating semen quality. The method comprises the following specific steps: 1, collecting a fresh liquefied seminal fluid sample, washing semen with a phosphate buffer solution or a BWW culture solution, removing residual seminal plasma constituents completely, and then conducting centrifugal separation on the semen; 2, adding cell lysis buffer and a protease inhibiting agent cocktail to the semen obtained through separation in step 1, mixing the mixture to be uniform, and after no obvious cell sedimentation is found, in other words, complete splitting decomposition is achieved, conducting high speed centrifugation at the temperature of 4 DEG C, wherein supernatant is protein extract; 3, measuring the protein concentration of the protein extract; 4, measuring sialidase activity of the semen, and finally obtaining the sialidase activity value / protein concentration value, so that the process is ended. According to the method, through detection of activity of sialidase in the semen, the diagnosis basis and clinical reference are provided for a patient suffering from male infertility with the clinical reasons unclear.

The present invention provides mutants of PmST1 for the preparation of sialyl-Lewisx oligosaccharides, and other sialosides with decreased sialidase activity.

The present invention relates to the properties of certain glycosyltransferase variants with N-terminal truncating deletions or internal deletions. Any of the mutants disclosed herein exhibit α-2,6-sialyltransferase enzymatic activity in the presence of CMP-activated sialic acid as a co-substrate and in the presence of a suitable acceptor site. A fundamental finding documented in the present invention is that such enzymes are not only able to catalyze the transfer of sialidyl moieties, but they are also able to catalyze the hydrolytic cleavage of terminally bound sialic acids from glycans. Specifically, it was found that in the presence of cytidine-5'-monophosphate (CMP), glycosyltransferase activity is inhibited and sialidase activity is stimulated. Sialidase activity was found to be dependent on the presence of a specific stretch of amino acids (positions 90-108) in the polypeptide sequence of the reference (wild-type) hST6 Gal-I polypeptide. Deletion of part of this sequence in N-terminal truncated variants was found to abolish sialidase activity, especially in the presence and absence of CMP. Thus, compositions, uses and methods employing the CMP-mediated feedback regulation documented herein are disclosed.

Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile. As such, the level of lysosomal exocytosis activity and / or lysosomal sialidase activity is predictive of a diagnosis and / or prognosis of cancer, chemotherapy resistance or dementia associated with Alzheimer's disease.

The invention relates to detection of sialidase activity by an aggregation induced luminescence probe. In particular, the invention relates to two tetrastyrene compounds containing sialic acid glycosyl units, and a preparation method and an application thereof in sialidase detection. The compounds disclosed by the invention have the structures shown in the formulas (I and II). Three or four sialicacid glycosyl units are contained and the sialic acid glycosyl units are connected onto tetrastyrene through triazole and pentaerythritol. The compounds can be applied to detection of sialidase and have application value in the diagnosis of diseases related to sialidase.